FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208126771> ?p ?o ?g. }

• W3208126771 endingPage "2098" @default.
• W3208126771 startingPage "2085" @default.
• W3208126771 abstract "With the progress made in the widespread application of interventional radiology procedures, there has been an increasing number of patients who suffer from cardiovascular diseases and go through imaging and interventional treatment with iodine contrast medium (ICM) year by year. In turn, there has been an increasing amount of concern over acute kidney injury (AKI) brought about by ICM. As evidenced by numerous studies, the initiation of inflammatory response plays a critical role in the development of ICM-induced AKI. Correspondingly, the strategy of targeting renal inflammatory response and cytokine release could provide an effective solution to mitigating the ICM-induced AKI. Moreover, Ginsenoside Rb1 (GRb1) constitutes one of the major active components of ginseng and features a wide range of vital biological functions. Judging from the research findings, GRb1 could impose antioxidant and anti-inflammatory effects on cardiovascular diseases, in addition to lung, liver and kidney diseases. However, reports on whether GRb1 could impose a protective effect against contrast-induced nephropathy (CIN) are absent. In this study, we have examined the therapeutic effects imposed by GRb1 as well as the potential molecular mechanism by establishing an in vivo and in vitro model of CIN. In addition, we have set up a mouse model of CIN through sequential intravenous injection of indomethacin, N(ω)-nitro-Larginine methyl ester (L-NAME), and iopromide. To further enhance the bioavailability of GRb1, we have encapsulated GRb1 with polyethylene glycol (PEG)/poly lactic-co-glycolic acid (PLGA) nanocarriers to generate GRb1 nanoparticles (NPs) conducting the in vivo experiments. During the in vitro experiments, we have adopted GRb1 to treat NRK-52E cells or cells transfected with the high mobility group box 1 gene (HMGB1) overexpression plasmid. As shown by the in vivo experimental results, GRb1 NPs could evidently improve the renal dysfunction in CIN, diminish the extent of apoptosis of tubular epithelial cells, and reduce the expression of high mobility group box 1 (HMGB1) and cytokines (tumor necrosis factor (TNF-α), interleukin (IL) 6 and IL-1β). In addition, GRb1 NPs are found to be capable of preventing the activation of Toll-like receptor 4 (TLR4)/NF-κB signaling pathway triggered by contrast medium. The in vitro experimental results have exactly confirmed the findings of the in vivo experiments. In the meantime, through the observation of the in vitro assays, overexpression of HMGB1 can partially counteract the beneficial effects imposed by GRb1. Judging from our research data, GRb1 could impose a protective effect against CIN by inhibiting inflammatory response via HMGB1/TLR4/NF-κB pathway, whereas HMGB1 constitutes a critical molecular target of GRb1." @default.
• W3208126771 created "2021-11-08" @default.
• W3208126771 creator A5009028848 @default.
• W3208126771 creator A5017300922 @default.
• W3208126771 creator A5043853478 @default.
• W3208126771 creator A5059006331 @default.
• W3208126771 creator A5070144271 @default.
• W3208126771 creator A5084195289 @default.
• W3208126771 date "2021-10-01" @default.
• W3208126771 modified "2023-09-23" @default.
• W3208126771 title "Protective Effect of Ginsenoside Rb1 Nanoparticles Against Contrast-Induced Nephropathy by Inhibiting High Mobility Group Box 1 Gene/Toll-Like Receptor 4/NF-κB Signaling Pathway" @default.
• W3208126771 cites W1518547765 @default.
• W3208126771 cites W1581476272 @default.
• W3208126771 cites W1958190914 @default.
• W3208126771 cites W2011944584 @default.
• W3208126771 cites W2057368294 @default.
• W3208126771 cites W2086531732 @default.
• W3208126771 cites W2123071874 @default.
• W3208126771 cites W2133772134 @default.
• W3208126771 cites W2147051256 @default.
• W3208126771 cites W2156729042 @default.
• W3208126771 cites W2409779133 @default.
• W3208126771 cites W2552903800 @default.
• W3208126771 cites W2556474302 @default.
• W3208126771 cites W2557104256 @default.
• W3208126771 cites W2566098525 @default.
• W3208126771 cites W2569191390 @default.
• W3208126771 cites W2584008148 @default.
• W3208126771 cites W2613098449 @default.
• W3208126771 cites W275847830 @default.
• W3208126771 cites W2895874686 @default.
• W3208126771 cites W2896727551 @default.
• W3208126771 cites W3047917478 @default.
• W3208126771 cites W3145815988 @default.
• W3208126771 doi "https://doi.org/10.1166/jbn.2021.3163" @default.
• W3208126771 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34706808" @default.
• W3208126771 hasPublicationYear "2021" @default.
• W3208126771 type Work @default.
• W3208126771 sameAs 3208126771 @default.
• W3208126771 citedByCount "5" @default.
• W3208126771 countsByYear W32081267712022 @default.
• W3208126771 countsByYear W32081267712023 @default.
• W3208126771 crossrefType "journal-article" @default.
• W3208126771 hasAuthorship W3208126771A5009028848 @default.
• W3208126771 hasAuthorship W3208126771A5017300922 @default.
• W3208126771 hasAuthorship W3208126771A5043853478 @default.
• W3208126771 hasAuthorship W3208126771A5059006331 @default.
• W3208126771 hasAuthorship W3208126771A5070144271 @default.
• W3208126771 hasAuthorship W3208126771A5084195289 @default.
• W3208126771 hasConcept C126838900 @default.
• W3208126771 hasConcept C134018914 @default.
• W3208126771 hasConcept C150903083 @default.
• W3208126771 hasConcept C18150654 @default.
• W3208126771 hasConcept C203014093 @default.
• W3208126771 hasConcept C207001950 @default.
• W3208126771 hasConcept C2778569047 @default.
• W3208126771 hasConcept C2778690821 @default.
• W3208126771 hasConcept C2778754328 @default.
• W3208126771 hasConcept C2779786684 @default.
• W3208126771 hasConcept C2780035454 @default.
• W3208126771 hasConcept C2781184683 @default.
• W3208126771 hasConcept C555293320 @default.
• W3208126771 hasConcept C71924100 @default.
• W3208126771 hasConcept C86803240 @default.
• W3208126771 hasConcept C98274493 @default.
• W3208126771 hasConceptScore W3208126771C126838900 @default.
• W3208126771 hasConceptScore W3208126771C134018914 @default.
• W3208126771 hasConceptScore W3208126771C150903083 @default.
• W3208126771 hasConceptScore W3208126771C18150654 @default.
• W3208126771 hasConceptScore W3208126771C203014093 @default.
• W3208126771 hasConceptScore W3208126771C207001950 @default.
• W3208126771 hasConceptScore W3208126771C2778569047 @default.
• W3208126771 hasConceptScore W3208126771C2778690821 @default.
• W3208126771 hasConceptScore W3208126771C2778754328 @default.
• W3208126771 hasConceptScore W3208126771C2779786684 @default.
• W3208126771 hasConceptScore W3208126771C2780035454 @default.
• W3208126771 hasConceptScore W3208126771C2781184683 @default.
• W3208126771 hasConceptScore W3208126771C555293320 @default.
• W3208126771 hasConceptScore W3208126771C71924100 @default.
• W3208126771 hasConceptScore W3208126771C86803240 @default.
• W3208126771 hasConceptScore W3208126771C98274493 @default.
• W3208126771 hasIssue "10" @default.
• W3208126771 hasLocation W32081267711 @default.
• W3208126771 hasLocation W32081267712 @default.
• W3208126771 hasOpenAccess W3208126771 @default.
• W3208126771 hasPrimaryLocation W32081267711 @default.
• W3208126771 hasRelatedWork W1982235147 @default.
• W3208126771 hasRelatedWork W2020579547 @default.
• W3208126771 hasRelatedWork W2021100442 @default.
• W3208126771 hasRelatedWork W2350362814 @default.
• W3208126771 hasRelatedWork W2381529287 @default.
• W3208126771 hasRelatedWork W3036327439 @default.
• W3208126771 hasRelatedWork W4205726400 @default.
• W3208126771 hasRelatedWork W4225979818 @default.
• W3208126771 hasRelatedWork W4317513702 @default.
• W3208126771 hasRelatedWork W2496415593 @default.
• W3208126771 hasVolume "17" @default.
• W3208126771 isParatext "false" @default.

• next